[PSMA-radioguided surgery in localised recurrent prostate cancer]
Standard
[PSMA-radioguided surgery in localised recurrent prostate cancer] : Urologe A. / Horn, T.; Rauscher, I.; Eiber, M.; Gschwend, J. E.; Maurer, T.
in: UROLOGE, Jahrgang 56, Nr. 11, 2017, S. 1417-1423.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - [PSMA-radioguided surgery in localised recurrent prostate cancer]
T2 - Urologe A
AU - Horn, T.
AU - Rauscher, I.
AU - Eiber, M.
AU - Gschwend, J. E.
AU - Maurer, T.
N1 - 1433-0563 Horn, T Rauscher, I Eiber, M Gschwend, J E Maurer, T Journal Article Review Germany Urologe A. 2017 Nov;56(11):1417-1423. doi: 10.1007/s00120-017-0516-z.
PY - 2017
Y1 - 2017
N2 - Recently, prostate-specific membrane antigen radioguided surgery (PSMA-RGS) was introduced for targeted resection of localised prostate cancer recurrence. Preliminary results show that PSMA-RGS is very sensitive and specific in tracking suspicious lesions intraoperatively. Prerequisite for PSMA-RGS is a positive (68)Ga-PSMA positron emission tomography (PET) scan with a preferably singular soft tissue or lymph node recurrence. The first 63 patients treated with PSMA-RGS were analyzed. The extracorporal analysis of a total of 277 tissue specimens yielded the following test quality criteria regarding the presence of malignant tissue: sensitivity 86.2%, specificity 96.4%, positive predictive value 94%, negative predictive value 91.5%. Oncological follow-up data was available from 59 patients. There was a drop in PSA (prostate specific antigen) below 0.2 ng/ml in 38 patients (67%). Of these 38 patients, 17 (45%) are free of biochemical recurrence after a median follow-up of 12.3 months (6.7-31.9 months). Clavien-Dindo grade III complications occurred in 6 of 63 patients (9.5%). In summary, PSMA-RGS proved to be of high value in patients with localised prostate cancer recurrence for exact localisation and resection of oftentimes small metastatic tissue using intraoperative and ex vivo gamma-probe measurements. Furthermore, PSMA-RGS has the potential to positively influence oncological outcomes. However, patient identification on the basis of (68)Ga-PSMA PET imaging and clinical parameters is crucial to obtain satisfactory results.
AB - Recently, prostate-specific membrane antigen radioguided surgery (PSMA-RGS) was introduced for targeted resection of localised prostate cancer recurrence. Preliminary results show that PSMA-RGS is very sensitive and specific in tracking suspicious lesions intraoperatively. Prerequisite for PSMA-RGS is a positive (68)Ga-PSMA positron emission tomography (PET) scan with a preferably singular soft tissue or lymph node recurrence. The first 63 patients treated with PSMA-RGS were analyzed. The extracorporal analysis of a total of 277 tissue specimens yielded the following test quality criteria regarding the presence of malignant tissue: sensitivity 86.2%, specificity 96.4%, positive predictive value 94%, negative predictive value 91.5%. Oncological follow-up data was available from 59 patients. There was a drop in PSA (prostate specific antigen) below 0.2 ng/ml in 38 patients (67%). Of these 38 patients, 17 (45%) are free of biochemical recurrence after a median follow-up of 12.3 months (6.7-31.9 months). Clavien-Dindo grade III complications occurred in 6 of 63 patients (9.5%). In summary, PSMA-RGS proved to be of high value in patients with localised prostate cancer recurrence for exact localisation and resection of oftentimes small metastatic tissue using intraoperative and ex vivo gamma-probe measurements. Furthermore, PSMA-RGS has the potential to positively influence oncological outcomes. However, patient identification on the basis of (68)Ga-PSMA PET imaging and clinical parameters is crucial to obtain satisfactory results.
KW - Aged Antigens, Surface/analysis Edetic Acid/analogs & derivatives Glutamate Carboxypeptidase II/analysis Humans Lymphatic Metastasis/diagnostic imaging/pathology Male Middle Aged Neoplasm Grading Neoplasm Recurrence, Local/diagnostic imaging/pathology/sur
U2 - 10.1007/s00120-017-0516-z
DO - 10.1007/s00120-017-0516-z
M3 - SCORING: Zeitschriftenaufsatz
VL - 56
SP - 1417
EP - 1423
JO - UROLOGE
JF - UROLOGE
SN - 0340-2592
IS - 11
ER -